SpringWorks Therapeutics (NASDAQ:SWTX) Earns “Equal Weight” Rating from Barclays
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by equities researchers at Barclays in a research note issued to investors on Monday, MarketBeat reports. They presently have a $47.00 target price on the stock, down from their prior target price of $63.00. Barclays‘s price target would indicate a potential […]
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by equities researchers at Barclays in a research note issued to investors on Monday, MarketBeat reports. They presently have a $47.00 target price on the stock, down from their prior target price of $63.00. Barclays‘s price target would indicate a potential […]
